Piramal Healthcare reported yesterday that it has settled a patent litigation over Baxter Healthcare's anesthetic drug Suprane and could now launch its product in the U.S. market starting Jan. 1, 2014, according to a Business-Standard report.
Piramal Critical Care, a subsidiary of Piramal Healthcare, announced that patent litigation with Baxter Healthcare regarding generic anesthetic Suprane has been dismissed by the Delaware District Court pursuant to a settlement between the parties.
As per the terms of the agreement, both parties agreed that Piramal may launch its generic Desflurane in the United States as of Jan. 1, 2014, subject to regulatory approval.
Related Articles on Anesthesia:
Heat, Extreme Exercise Can Trigger Malignant Hyperthermia
Local Anesthesia Effective for Oculofacial Surgery
Elements of a Successful Anesthesia Service in ASCs
Piramal Critical Care, a subsidiary of Piramal Healthcare, announced that patent litigation with Baxter Healthcare regarding generic anesthetic Suprane has been dismissed by the Delaware District Court pursuant to a settlement between the parties.
As per the terms of the agreement, both parties agreed that Piramal may launch its generic Desflurane in the United States as of Jan. 1, 2014, subject to regulatory approval.
Related Articles on Anesthesia:
Heat, Extreme Exercise Can Trigger Malignant Hyperthermia
Local Anesthesia Effective for Oculofacial Surgery
Elements of a Successful Anesthesia Service in ASCs